Appreciate the client service support: on going clear communication, in timely manner, very pleasant demeanor. Also truly appreciate the attention to detail and accuracy in the report. This is a strong advantage over other suppliers.
As a member of the MD Analytics Panel: Perspectives in Health, you will have the opportunity to share your opinions and expertise on a variety of topics related to treatments, diagnostic tests, health policy and other health-related products and services.
Join the MD Analytics Panel: Perspectives in Health to be invited to participate in paid health-related market research studies, such as online surveys, virtual interviews, and in-person focus groups.
MD Analytics provides market research services for the healthcare and pharmaceutical industry. We are committed to following the highest standards and care within our industry, abiding by the codes of conduct of the Canadian Research Insights Council, ESOMAR, and the Insights Association.
Participating in our market research studies provides opportunities for healthcare professionals to voice their opinions and inform key decisions impacting health policy and patient care. Participants also benefit from learning opportunities obtained through participating in market research and from incentives earned in exchange for their time and expert contribution.
Upon signing up to join the panel, you will be sent invitations via email to participate in online surveys, telephone interviews and/or focus groups that are relevant to your health profession and area of specialty. The study invitation will always indicate the type of study, topic, length of time required to complete the study and the incentive amount.
You decide whether a study interests you and participate as you wish. Upon completing a study, you will be paid the incentive specified.
What will the content of the survey be used for and for whom?
The research sponsor and purpose will vary depending on the study. To not bias the research, we are unable to reveal their identity. However, most of our clients are multi-national pharmaceutical companies specializing in developing products and treatments for the therapeutic area of the study topic.
Are my responses anonymous?
Absolutely, your responses are anonymous. As a third-party market research firm, we never share your personal identifiable information with the research sponsor. Your responses will never be tied back to you as an individual. We always present the research findings as an aggregate between what you and your colleagues have collectively answered.
Will my name, title, or contact information be shared with research sponsors or publications?
No, we will never share that information to our clients nor any publications. If we need data from any of our physician panelists for a publication, we will state it explicitly in the first page of the survey and will ask for your consent to proceed.
How do I know if I qualify to participate?
Every online survey starts with a short eligibility section followed by the main survey. Each survey has different screening requirements, so we cannot guarantee eligibility every time. Every eligibility section will typically take from 15 seconds up to 2 minutes of your time.
What do you do with the data collected in the eligibility section?
We discard the data from the eligibility section, if you do not qualify to answer the main study questions. The data from the eligibility section is used for profiling and it is not useful for the study if it is not coupled with answers for the main survey.
How do I verify if the research is legitimate?
You can search the validity of our studies on the CRIC research verification service.
Appreciate the client service support: on going clear communication, in timely manner, very pleasant demeanor. Also truly appreciate the attention to detail and accuracy in the report. This is a strong advantage over other suppliers.
Great work. The bar is pretty high now.
This project was one of my most complicated to date. Great job from the team.
Excellent experience working with the MD Analytics team on this project. They went out of their way to move quickly to meet our deadlines and went above and beyond to support us with the results. Would love to partner again in the future.
Corporate reputation plays an important role in enabling companies to further differentiate their products in highly competitive markets. As a result our team sought to better understand how pharmaceutical manufacturers are currently perceived. After surveying Canadian GPs, we noticed several trends....
Modern Blood Glucose Meter (BGM) devices can often pair with a companion app on a smartphone, which allows patients to easily record and monitor their blood glucose levels over time. This gives the patient, and potentially their doctor, easy to access historical data, insightful charts, and other information that can aid in diabetes management. Research was conducted by MD Analytics to assess whether Canadian GPs are accepting this technology, and if it plays a role in their recommendation of one BGM over another....
Smart Drugs (or nootropics) are substances used to enhance cognitive functions. Exact usage numbers are difficult to ascertain, but a recent study conducted among UBC students found that 1 in 30 students admitted using ADHD medication they were not prescribed, for their cognitive effects. The use of Smart Drugs appears to be gaining momentum in Canada, especially among students and young professionals in high pressure situations, thereby having the potential to turn into a public health issue....
The relationship between healthcare providers and sales reps is a balancing act. Managed well they can add value to a physicians' or pharmacist’s practice ultimately impacting product use. However HCPs are often overwhelmed by the demand on their time and as a result may restrict access to their practices to sales reps....
With the emergence of Complementary and Alternative Medicine (CAM), prescription options alone are no longer the norm as it pertains to treating a number of medical conditions. Research among 170 Canadian physicians shows that CAM therapies are not only common practice for many already, but are expected to become even more widely accepted as viable treatment options within the conventional medical community....
Biomarkers are molecules found in bodily fluids or tissues (including the tumor tissue). They provide valuable information about the cancer cells and non-cancer cells when analyzing which biomarkers are produced in response to the cancer. By developing a biomarker profile of a patient’s cancer, doctors can recommend the best suited treatment plan for their patient....
Traditional in-person continuing health education (CHE) programs remain the most attended format for Canadian physicians practitioners, however preferred sources of CHE vary widely by generation. As educational activities are an important channel to communicate important scientific data about new treatment options, program success will benefit from a tailored approach to CHE delivery....
Dental professionals turn to traditional information channels most often when sourcing information on manufacturer products and continuing education. However, more innovative tools such as online and digital offerings continue to grow in importance, especially among newer dental professionals. Find out how to make sure your future outreach efforts are ready for the next generation of dental professionals....
The Canadian Senate recently passed Bill C-46 which will allow for the legal use of recreational cannabis across Canada by Fall 2018. While some physicians anticipate this new legislation will impact their practices with patients electing to try recreational cannabis instead of more traditional prescription medications or medical cannabis, others anticipate increases in patient visits related to dependence and psychotic symptoms....
Biological drugs, protein-based products derived from living cells using biotechnology, have been used since the 1990’s as a treatment option for cancer patients. Since 2009, biosimilar therapies (therapeutically equivalent subsequent entry biologics) have been available in different therapeutic areas in Canada, and are now on the verge of becoming available for use in oncology....
Ready to explore how data-driven insights can accelerate your pharmaceutical research? Connect with our team to discuss your goals.